跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
MSLN-CAR-T
首页
药物
MSLN-CAR-T
MSLN-CAR-T
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
METHODS FOR TREATING CANCER
EP 4774292 A1
申请人: UNIV CALIFORNIA
优先权: 2023
CN
EP
WO
3 件公开
Dual chimeric antigen receptor-t cell which can be regulated, construction method therefor and use thereof
US 11932872 B2
申请人: NANJING ANJI BIOLOGICAL TECH CO LTD
优先权: 2017
CN
US
2 件公开
USE OF SODIUM BICARBONATE IN PREPARATION OF ENHANCER FOR MSLN-CAR-T TREATMENT OF SOLID TUMORS
WO 2026061439 A1
申请人: THE FIRST AFFILIATED HOSPITAL SOUTHWEST HOSPITAL OF ARMY MEDICAL UNIV
优先权: 2024
CN
WO
2 件公开
APPLICATION OF PANTOPRAZOLE IN PREPARATION OF ENHANCER FOR MSLN-CAR-T CELL THERAPY AGAINST BRAIN METASTASES
WO 2026061436 A1
申请人: THE FIRST AFFILIATED HOSPITAL SOUTHWEST HOSPITAL OF ARMY MEDICAL UNIV
优先权: 2024
CN
WO
2 件公开
MSLN-SPECIFIC CHIMERIC ANTIGEN RECEPTOR, CAR-T CELL AND USE THEREOF
WO 2026118738 A1
申请人: SHANGHAI YIHAO BIOTECHNOLOGY CO LTD
优先权: 2024
CN
WO
2 件公开
RECOMBINANT VECTORS, LENTIVIRUSES, LUNG-EXEMPT MSLN CAR-T CELLS, AND ANTI-TUMOR AGENTS
US 20260183338 A1
申请人: TONGJI HOSPITAL TONGJI MEDICAL COLLEGE OF HUAZHONG UNIV OF SCIENCE AND TECHNOLOGY
优先权: 2024
CN
US
2 件公开
Method for knocking out PD-1 gene by utilizing CRISPR/Cas9 technology to construct MSLN-targeted novel CAR-T cell and application of method
CN 106480097 A
申请人: NANJING KAEDI BIOTECH INC
优先权: 2016
CN
具有自杀基因开关的靶向人间皮素的工程化免疫细胞
CN 109593721 B
申请人: 亘喜生物科技(上海)有限公司
优先权: 2017
CN
以MSLN为靶点的嵌合抗原受体
CN 109111528 B
优先权: 2018
CN
Chimeric antigen receptor DAP12-T2A-CD8alpha-MSLN scFv-NKp44 and purpose thereof
CN 109467605 A
申请人: NANJING CART MEDICAL TECH LTD
优先权: 2018
CN
第 1 / 5 页
上一页
下一页
药物
反馈